Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 39Unknown 7Terminated 7Withdrawn 5Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Pediatric Solid Tumor, Unspecified, Protocol Specific 1

Interventions

pembrolizumab 555Specimen Handling 459Carboplatin 446Magnetic Resonance Spectroscopy 427Cyclophosphamide 412Cisplatin 404Gemcitabine 314Radiotherapy 313Bevacizumab 310Paclitaxel 300Biopsy 260Drug Therapy 252Capecitabine 241Oxaliplatin 240fludarabine 236Nivolumab 226venetoclax 225Injections 214Docetaxel 203Fluorouracil 201Dexamethasone 186Radiosurgery 172Rituximab 161Pemetrexed 157durvalumab 144Standard of Care 143atezolizumab 139toripalimab 137tislelizumab 137Leucovorin 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Interventional × Ondansetron × Clear all
NCT06208917 2024-01-17

Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children

Sun Yat-sen University

Phase 3 Recruiting
376 enrolled
Other solid neoplasm

Pediatric Solid Tumor, Unspecified, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡